{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:43:21Z","timestamp":1789181001018,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.amjcard.2019.12.030","type":"journal-article","created":{"date-parts":[[2019,12,26]],"date-time":"2019-12-26T19:51:11Z","timestamp":1577389871000},"page":"874-879","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the Veterans Affairs Healthcare System)"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7949-6173","authenticated-orcid":false,"given":"Xiaoming","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Ramsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud Al","family":"Rifai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah T.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia M.","family":"Akeroyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7560-9521","authenticated-orcid":false,"given":"Dave L.","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ty J.","family":"Gluckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Nambi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil J.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim S.","family":"Virani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2019.12.030_bib0001","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2019.12.030_bib0002","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2019.12.030_bib0003","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2019.12.030_bib0004","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ahj.2016.07.020","article-title":"Comparative effectiveness of outpatient cardiovascular disease and diabetes care delivery between advanced practice providers and physician providers in primary care: implications for care under the Affordable Care Act","volume":"181","author":"Virani","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2019.12.030_bib0005","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1532-5415.2011.03784.x","article-title":"Treating chronically ill people with diabetes mellitus with limited life expectancy: implications for performance measurement","volume":"60","author":"Woodard","year":"2012","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.amjcard.2019.12.030_bib0006","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/clc.22503","article-title":"Statin use and its facility-level variation in patients with diabetes: insight from the Veterans Affairs national database","volume":"39","author":"Pokharel","year":"2016","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.amjcard.2019.12.030_bib0007","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1177\/1358863X18758914","article-title":"Statin prescription rates and their facility-level variation in patients with peripheral artery disease and ischemic cerebrovascular disease: insights from the Department of Veterans Affairs","volume":"23","author":"McBride","year":"2018","journal-title":"Vasc Med"},{"key":"10.1016\/j.amjcard.2019.12.030_bib0008","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1161\/CIRCULATIONAHA.113.003589","article-title":"Patterns of statin initiation, intensification, and maximization among patients hospitalized with an acute myocardial infarction","volume":"129","author":"Arnold","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2019.12.030_bib0009","doi-asserted-by":"crossref","first-page":"e006460","DOI":"10.1161\/JAHA.117.006460","article-title":"Lipid testing and statin dosing after acute myocardial infarction","volume":"7","author":"Wang","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2019.12.030_bib0010","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.ahj.2010.09.008","article-title":"Lipid-lowering intensification and low-density lipoprotein cholesterol achievement from hospital admission to 1-year follow-up after an acute coronary syndrome event: results from the Medications ApplIed aNd SusTAINed Over Time (MAINTAIN) registry","volume":"160","author":"Melloni","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2019.12.030_bib0011","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1161\/CIRCULATIONAHA.111.038265","article-title":"Statin use in outpatients with obstructive coronary artery disease","volume":"124","author":"Arnold","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2019.12.030_bib0012","doi-asserted-by":"crossref","first-page":"e005699","DOI":"10.1161\/JAHA.117.005699","article-title":"High-intensity statin therapy is associated with improved survival in patients with peripheral artery disease","volume":"6","author":"Foley","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2019.12.030_bib0013","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1001\/jamacardio.2017.2289","article-title":"Simulation of lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease","volume":"2","author":"Cannon","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.amjcard.2019.12.030_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2011.07.013","article-title":"Frequency and correlates of treatment intensification for elevated cholesterol levels in patients with cardiovascular disease","volume":"162","author":"Virani","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2019.12.030_bib0015","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009251","article-title":"Measurement of low-density lipoprotein cholesterol levels in primary and secondary prevention patients: insights from the PALM registry","volume":"7","author":"Lowenstern","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2019.12.030_bib0016","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2019.12.030_bib0017","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2019.12.030_bib0018","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/eurheartj\/ehw046","article-title":"Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents","volume":"37","author":"Ridker","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2019.12.030_bib0019","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1001\/jamacardio.2018.4936","article-title":"Association of statin adherence with mortality in patients with atherosclerotic cardiovascular disease","volume":"4","author":"Rodriguez","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.amjcard.2019.12.030_bib0020","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2019.12.030_bib0021","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2019.12.030_bib0022","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"10.1016\/j.amjcard.2019.12.030_bib0023","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00019053-200422003-00003","article-title":"Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy","volume":"22","author":"Benner","year":"2004","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.amjcard.2019.12.030_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2015.11.002","article-title":"Provider understanding of the 2013 ACC\/AHA cholesterol guideline","volume":"10","author":"Virani","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.amjcard.2019.12.030_bib0025","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.amjmed.2015.10.024","article-title":"2013 cholesterol guidelines revisited: percent LDL cholesterol reduction or attained LDL cholesterol level or both for prognosis?","volume":"129","author":"Bangalore","year":"2016","journal-title":"Am J Med"},{"key":"10.1016\/j.amjcard.2019.12.030_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2017.11.010","article-title":"Clinical pharmacist understanding of the 2013 American College of Cardiology\/American Heart Association cholesterol guideline","volume":"12","author":"Bucheit","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.amjcard.2019.12.030_bib0027","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1001\/jamainternmed.2013.8198","article-title":"Correlates of repeat lipid testing in patients with coronary heart disease","volume":"173","author":"Virani","year":"2013","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.amjcard.2019.12.030_bib0028","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jacc.2015.02.003","article-title":"2015 ACC\/AHA focused update of secondary prevention lipid performance measures: a report of the American College of Cardiology\/American Heart Association Task Force on Performance Measures","volume":"67","author":"Drozda","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2019.12.030_bib0029","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1016\/j.jacc.2017.06.032","article-title":"2017 AHA\/ACC clinical performance and quality measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology\/American Heart Association task force on performance measures","volume":"70","author":"Jneid","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2019.12.030_bib0030","doi-asserted-by":"crossref","first-page":"e693","DOI":"10.1016\/j.amjmed.2019.04.002","article-title":"Association between lipid testing and statin adherence in the Veterans Affairs health system","volume":"132","author":"Jia","year":"2019","journal-title":"Am J Med"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914919314997?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914919314997?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:32:46Z","timestamp":1757572366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914919314997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0002914919314997"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2019.12.030","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the Veterans Affairs Healthcare System)","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2019.12.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}